Abbott Laboratories $ABT Stock Acquired by Hohimer Wealth Management LLC

Posted by Geri Gentry on Nov 9th, 2026

Hohimer Wealth Management LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 22.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 30,504 shares of the healthcare product maker’s stock after purchasing an additional 5,557 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Abbott Laboratories were worth $3,015,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Carret Asset Management LLC increased its holdings in shares of Abbott Laboratories by 3.2% in the third quarter. Carret Asset Management LLC now owns 52,300 shares of the healthcare product maker’s stock valued at $5,169,000 after purchasing an additional 1,605 shares during the period. University of Texas Texas AM Investment Management Co. raised its stake in shares of Abbott Laboratories by 51.5% in the third quarter. University of Texas Texas AM Investment Management Co. now owns 1,797 shares of the healthcare product maker’s stock worth $178,000 after purchasing an additional 611 shares during the last quarter. M Holdings Securities Inc. purchased a new position in shares of Abbott Laboratories in the third quarter worth about $1,403,000. Brighton Jones LLC lifted its holdings in shares of Abbott Laboratories by 5.8% during the third quarter. Brighton Jones LLC now owns 71,630 shares of the healthcare product maker’s stock worth $7,079,000 after purchasing an additional 3,957 shares during the period. Finally, Candriam S.C.A. boosted its position in Abbott Laboratories by 445.2% in the third quarter. Candriam S.C.A. now owns 1,151,288 shares of the healthcare product maker’s stock valued at $114,198,000 after buying an additional 940,121 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the transaction, the executive vice president owned 100,791 shares in the company, valued at approximately $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Barclays started coverage on shares of Abbott Laboratories in a report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Argus cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Finally, Robert W. Baird boosted their target price on shares of Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $118.32.

Read Our Latest Stock Analysis on Abbott Laboratories

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $110.02 on Monday. The company has a market capitalization of $190.38 billion, a PE ratio of 41.05, a price-to-earnings-growth ratio of 1.93 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. The company’s fifty day moving average price is $104.04 and its 200 day moving average price is $101.78. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The company had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. During the same quarter in the previous year, the company earned $1.30 earnings per share. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. On average, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 94.03%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings.

Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac.